ClinicalTrials.gg
RecruitingNCT06376448Updated Aug 1, 2025

An Observational Study Using Novel Questionnaire to Characterize Cough Phenotypes in Patients With Chronic Cough

An observational study in Chronic Cough, sponsored by Hull University Teaching Hospitals NHS Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-01.

Sponsored by Hull University Teaching Hospitals NHS Trust · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Started Oct 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Chronic Cough with a site in United Kingdom — 4 open to participants now, 5 under way, none of them phase 3. Chronic Cough · United Kingdom.

Started
2022
with 2 others
Observational
7 of 36
2 open now
Registered
31st of 36
by date
Lead sponsor
2 of 36
Hull University Teaching Hospitals NHS Trust

Among the 36 studies in Chronic Cough with a site in United Kingdom, this one is one of 3 that started in 2022, is one of 7 observational ones, and was the 31st registered.

Chronic Cough

142 studies on the registry are indexed under Chronic Cough; 38 are open to participants now.

Browse Chronic Cough studies →

Open to participants now

4 of the 36 studies in Chronic Cough with a site in United Kingdom are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 30 Chronic Cough studies recruiting now, 10 (33%) set no upper age limit and 12 (40%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Chronic Cough with a site in United Kingdom, or all of them as a file.
02

Study summary

Cough has previously been described by the type of cough you have ie such as wet, dry, and chesty, and also by its features such as how often you are coughing its,intensity, and severity, but never has the varying patterns of cough been studied in any detail and it could be that the pattern of the cough is closely related to patient-perceived intensity, frequency and most importantly severity. Cough is a symptom and like any other symptom (such as pain) the severity of it can only be gauged by the patient experiencing it.

We have created a one-page brand newl questionnaire that shows 4 distinct cough patterns that we believe exist and an empty field designed so that patients can record a pattern of cough they experience which is not already a choice on the questionnaire. The questionnaire also records patients' experience of how frequent, and intense, the cough is, and how it disrupts their lives, on a 1-10 scale (Visual analogue scale), the sum of these scores is collated and this gives us a severity score. The first phase of the project is to determine whether 30 Chronic cough patients understand the questionnaire, and are able to complete it with little direction, and if the cough patterns we identified encompassed all pattern types. second part of the study is to look at how repeatable the questionnaire is when completed over a 6 week period.

Read the detailed description

STUDY DESIGN This is a single centre observational study.There are two parts to the study. Part 1. Comprises a screening and if suitable the patient will complete the novel questionnaire on one visit.

Part 2. Subjects will be screened, if suitable, patients will be asked to complete the questionnaire and 2-4 weeks later they will be asked to complete the questionnaire once more.

Informed consent and the screening assessment may be conducted either in person at the study site or by telephone, as detailed below.

Informed Consent at Site Potential subjects will be provided with the patient information sheet (PIS) and informed consent form (ICF) at site. A member of the research team will discuss the study with them and take them through the information contained within the PIS and ICF. The subject will be encouraged to ask questions to ensure full understanding. If having read and understood the PIS and ICF the subject wishes to participate, they will sign and date two copies of the ICF, keeping one copy for themselves.

Informed Consent By Telephone

Potential subjects will be sent the PIS and ICF by post or email. Once they have had time to receive and read them, a member of the research team will contact the subject by phone to discuss the study and talk them through the information contained within the PIS and ICF. The subject will be encouraged to ask questions to ensure full understanding. If having read and understood the PIS and ICF the subject gives verbal consent to participate, one of the two following processes will be followed:

  • If the full consent discussion has been witnessed at the site, the witness will sign the ICF to confirm that all aspects of the study have been discussed and the subject has freely given verbal informed consent. A copy of the signed ICF will then be sent to the subject.
  • If the consent discussion has not been witnessed at the site, the subject will sign and date two copies of the ICF, return one copy to the research team and keep the other copy for themselves.

During screening, eligibility is checked by reference to the selection criteria. If the subject is assessed as eligible for the study, they are assigned a 3-digit subject number. The 3 digit numbers for these patients taking part in part 1, will be prefixed with 1 and those for Part 2, prefixed with a 2.

COUGH PATTERN ASSESSMENTS Part 1. 30 Study participants will be asked to identify their pattern of cough from the patterns identified on the questionnaire, if the patient feels they are unable to identify their pattern then they will be asked to draw a diagram of the pattern and explain the pattern of their cough during the day. This group of patients will be asked to comment on the questionnaire to allow for any improvements. Based on this initial questionnaire completion by this cohort of patients the questionnaire may be updated, especially if new patterns of cough are identified.

Part 2. 30 study participants will be asked to complete the potentially updated questionnaire and then a further copy of the questionnaire will be posted out to these patients for completion 2 to 4 weeks following the first recording on the questionnaire.

Cough frequency/ intensity and disruption Numerical Rating Scale The Cough frequency/ intensity/ and disruption NRS is an 11-point rating scale that patients will be asked to complete.

Each scale is worded as per example below

Now we woud like you to rate how often (frequently) you are coughing , the strength (intensity ) of the cough and overall how disruptive you feel your cough is to your daily life

Please circle most relevant number on scale How often do you cough (Frequency) 0 1 2 3 4 5 6 7 8 9 10 0= no coughing

There are 11 numbered boxes and subjects should select the one that best matches their perception of cough frequency, intensity and disruption to life.

The scores reported on each scale will be summed up to give a total score for severity . This will range from 0-30.

03

Conditions studied

  • Chronic Cough

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients will be identified from those attending the chronic cough clinic or patients that have a history of chronic cough who have previously shown an interest in research.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female patients > 18yrs of age
  2. Patients with a current cough of at least 8 weeks duration
  3. Patients with a clear chest X-Ray within previous 2 yrs
  4. Non- smoker
  5. Able to understand and comply with the requirements of the study and sign forms.
  6. Good understanding of written and spoken English -

Exclusion criteria

Exclusion Criteria:

  1. Recent respiratory tract infection (\<4 weeks prior).
  2. Current smokers or ex-smokers with \<6 months' abstinence prior to Study.
  3. Any or unstable medical or psychiatric condition that would, in the opinion of the investigator, interfere with the subject's ability to participate in the study safely.
  4. Participation in any clinical research study evaluating an drug or therapy within 30 days or within 5 half-lives (whichever is longer) of the investigational drug prior to Study visit. If the subject was in an observational clinical study no is required.
  5. Subjects who, in the opinion of the Investigator, should not participate in the study for any other reason.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. The primary objective of the study is to characterize and identify the different patterns of cough in chronic cough patients

    describe % of various cough patterns recorded and gender differnces and any new patterns

    Time frame: 1 day

Secondary outcomes

  1. measure of cough severity

    To sum up the cough frequency, intensity and disruption to daily life VAS scores to give a measure of cough severity

    Time frame: 1 day

  2. describe any correlation between severity of cough and cough pattern

    To compare cough frequency, intensity and disruption to life with pattern of cough, to determine if any correlation.

    Time frame: 1 day

  3. reproducibility of questionnnare

    determine if questionnaire reproducible from repoerting at screening to 4 weeks later

    Time frame: 4 weeks

07

Study locations

1 of 1 sites recruiting
  • Redspiratory Medicine, First Floor, Daisy Building, Castle Hill Hospital
    Cottingham, East Yorkshiure HU16 5JQ, United Kingdom
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2022 (actual). Primary completion is estimated for Oct 2025, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2024
First posted
Apr 19, 2024
StartActual
Oct 24, 2022
Primary completionEst.
Oct 4, 2025
CompletionEst.
Dec 10, 2025
Last update
Aug 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06376448
Lead sponsor
Hull University Teaching Hospitals NHS Trust
Responsible party
Sponsor
First posted
Apr 19, 2024
Start date
Oct 24, 2022
Primary completion
Oct 4, 2025 (estimated)
Completion
Dec 10, 2025 (estimated)
Last update
Aug 1, 2025

Study contacts

Caroline Wright, BSc
Contact
c.wright@hull.ac.uk
01482624067
Rachel Thompson
Contact
r.h.thompson@hull.ac.uk
01482624009

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion